Do ACE inhibitors and ARBs increase the expression of ACE2? The role of drugs acting on the RAAS and their potential to enhance the risk of serious COVID-19 symptoms by increasing virus entry are ...

Researchers identify potential ACE2 inhibitors through a virtual screening protocol.

Chronic ACE2 inhibition increased urinary albumin excretion in diabetic mice, suggesting that ACE2 might be a new therapeutic target in kidney disease.

Called the angiotensin-converting enzyme 2, or ACE2 "receptor," the protein provides the entry point for the coronavirus to hook into and infect a wide range of human cells.

Researchers at Demokritus University of Thrace, Institute of Applied Biosciences Centre for Research and Technology Hellas, National Hellenic Research Foundation and University of Athens have ...

Mice taking angiotensin converting enzyme, or ACE, inhibitors were found to have higher levels of ACE2, a protein present on the surface of cells that is known to help the virus spread through the ...

ARBs and ACE inhibitors increase the expression of ACE2; a hypothesis that their use may modify susceptibility to infection with SARS-CoV-2 in humans has developed.

Research in experimental models has shown an increase in the number of ACE2 receptors in the cardiopulmonary circulation after intravenous infusions of ACE inhibitors.

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors. Blocking this interaction with inhibitors could ...

The loss of ACE2 in diabetes activates the vasodeleterious RAS axis and lessens the vasoprotective RAS axis. Intriguingly, in a mouse model of Type 1 diabetes, feeding mice with a modified gut ...